53 citations
,
January 1985 in “Acta obstetricia et gynecologica Scandinavica” This study found that an 8-month treatment with a low-dose oral contraceptive significantly reduced testosterone levels and hair growth in women with polycystic ovary syndrome and hirsutism, with minimal side effects.
52 citations
,
April 2008 in “Therapeutics and clinical risk management” This review covers the use of combined oral contraceptives, particularly drospirenone, for managing polycystic ovary syndrome and discusses related metabolic controversies without reporting new clinical results.
42 citations
,
December 1976 in “PubMed” This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.
13 citations
,
September 2011 in “American Journal of Clinical Dermatology” This review describes the dermatological uses of the contraceptive ethinylestradiol/chlormadinone acetate for conditions linked to high androgen levels and reports no new clinical results.
12 citations
,
August 2017 in “Pharmaceutical medicine” This study found that physician knowledge of thromboembolism risk associated with cyproterone acetate/ethinylestradiol was generally high, although it varied for complex or less common topics.
11 citations
,
October 1986 in “International Journal of Gynecology & Obstetrics” This study found that the combination of ethinylestradiol and desogestrel significantly decreased hair growth and hormone levels in hirsute women, suggesting a relationship between hormone changes and treatment effectiveness.
11 citations
,
April 2017 in “The European Journal of Contraception & Reproductive Health Care” This review highlights that Cyproterone acetate combined with ethinylestradiol is highly effective for treating severe acne and hirsutism in women with hyperandrogenism, and it also provides benefits for cycle control and mood improvement, according to the analysis of 78 studies.
6 citations
,
October 2016 in “Contraception” This study found that most UK women prescribed cyproterone acetate/ethinylestradiol before and after 2013 had conditions aligning with approved indications and prior acne treatment.
6 citations
,
March 2012 in “Journal of the European Academy of Dermatology and Venereology” This study found that 12 cycles of chlormadinone acetate in hormonal contraceptives significantly improved oily skin and hair quality, enhancing psychosocial well-being in healthy women.
5 citations
,
July 2020 in “PubMed” This study found that EE/CPA and EE/DES were both effective in reducing hirsutism in patients with PCOS, with no additional benefit from adding low-dose metformin.
5 citations
,
July 1987 in “European Journal of Obstetrics & Gynecology and Reproductive Biology” This study found that a combined oral contraceptive containing ethinyl estradiol and desogestrel appeared effective in temporarily treating ovarian hyperandrogenism in adolescents, with reductions in hormone levels and ovarian volume observed.
4 citations
,
September 2011 in “American Journal of Clinical Dermatology” This case series suggests that EE/CMA 0.03mg/2mg may help manage dermatological disorders related to androgen excess, as evidenced by symptomatic improvements in the four patients treated.
3 citations
,
April 2017 in “Clinical Drug Investigation” The researchers concluded that after the 2013 EMA recommendation, there was an overall reduction in CPA/EE prescriptions, but no substantial change in patient diagnoses or potential concurrent hormonal contraceptive use.
1 citations
,
March 2013 in “The European Journal of Contraception & Reproductive Health Care” This publication discusses the political rationale behind the French regulator ANSM's decision to withdraw Diane®-35 from the market, in response to health concerns associated with third-generation oral contraceptives.
1 citations
,
January 2004 in “Drugs” Ethinylestradiol/Chlormadinone Acetate is a safe and effective birth control pill that also helps regulate menstrual cycles, reduces period pain, and treats certain skin and hair conditions.
October 2024 in “Clinical and Experimental Dermatology” This study found that combining 17α-estradiol 0.01% with minoxidil 2% offered no statistically significant advantage over minoxidil alone for treating female pattern hair loss and may increase the risk of menstrual irregularities.
January 2024 in “International Journal of Dermatology Research” This randomized clinical trial found that both topical ethinylestradiol 0.01% combined with minoxidil 2% and minoxidil 2% alone were similarly effective in enhancing hair growth for female pattern hair loss, though minoxidil alone was better tolerated with fewer side effects over 24 weeks.
September 2021 in “GLOBAL JOURNAL FOR RESEARCH ANALYSIS” This study found that combined hormonal contraceptives containing ethenyl estradiol and cyproterone acetate improved acne, hirsutism, menstrual irregularity, and dysmenorrhea in patients with polycystic ovarian syndrome, with most participants showing significant symptom improvement after 6 to 12 months.
January 2021 in “Journal of Shaheed Suhrawardy Medical College” This study found that treatment with oral contraceptives containing 35mg ethinylestradiol and 2mg cyproterone acetate significantly reduced serum AMH levels in women with clomiphene citrate-resistant polycystic ovary syndrome, unlike metformin.
September 2018 in “Reactions Weekly” Two women had skin reactions from a hair loss treatment and got better after stopping use.
January 2009 in “The Chinese Journal of Modern Applied Pharmacy” This study concluded that QSPR models effectively predict drug skin penetration, with the Potts-Guy model showing the highest predictive accuracy for the drugs tested.
January 2025 in “American Journal of Translational Research” This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.
In this study, metformin, pioglitazone, and ethinylestradiol cyproterone all improved various clinical features and quality of life in Pakistani women with PCOS, though no drug significantly reduced hirsutism.
49 citations
,
June 1998 in “Journal of Endocrinological Investigation” In this study, both cyproterone acetate-estrogen combination (Diane®) and finasteride were effective in reducing hirsutism, but Diane® showed greater long-term efficacy and cost-effectiveness.
35 citations
,
July 2008 in “International Journal of Gynecology & Obstetrics” This study found that medroxyprogesterone acetate treatment in women with PCOS reduced hyperandrogenism-related hormonal levels and improved skin conditions without affecting lipid or carbohydrate metabolism.
31 citations
,
January 2008 in “Gynecological endocrinology” In this study, two different estroprogestin treatments significantly improved skin conditions and decreased androgen levels in hyperandrogenic women, with EE/DRSP showing more pronounced hormonal changes and skin improvements compared to EE/CMA.
20 citations
,
November 2015 in “International Journal of Gynecology & Obstetrics” Among women with polycystic ovary syndrome, this study found that oral contraceptives containing 20 μg ethinyl estradiol had similar effects on androgen levels as those containing 30 μg.
20 citations
,
July 1990 in “Clinical and experimental dermatology” In this study, women treated for androgen-dependent alopecia with CPA EE2 therapy experienced significant decreases in serum vitamin B12, hemoglobin, and hematocrit levels after six months.
18 citations
,
March 2010 in “Gynecologic and obstetric investigation” This study found that both combined therapy with goserelin and oral contraceptives, and oral contraceptives alone, significantly reduced hair diameter in severe hirsutism without a significant difference between treatments.
9 citations
,
December 1987 in “European journal of endocrinology” In this study, 12 months of cyproterone acetate and ethinyl oestradiol treatment significantly reduced hair growth rate and certain hormone levels in hirsute women, though hair density and prolactin levels remained unchanged.